Table 5. Results for the significantly opposing inflammatory gene variants in NMIBC patients with BCG treatment associated with progression in the discovery, validation and meta-analysis.
| Progression | Gene | MAF | MOI | Discovery | Validation | Meta-analysis | |||
|---|---|---|---|---|---|---|---|---|---|
| SNP | HR (95% CI)* | P-value | HR (95% CI)* | P-value | HR (95% CI) | P-value | |||
| rs1800686 | CD40 | 0.24 | rec | 3.81 (1.55-9.37) | <0.001 | 1.91 (0.72-5.03) | 0.191 | 2.77 (1.43-5.36) | 0.002 |
| rs2071081 | CD4 | 0.21 | rec | 3.19 (1.36-7.47) | 0.010 | 1.24 (0.43-3.53) | 0.693 | 2.19 (1.13-4.26) | 0.002 |
| rs7089861 | IL2RA | 0.28 | rec | 3.15 (1.38-7.22) | 0.006 | 3.84 (1.64-9.0) | 0.002 | 3.47 (1.92-6.28) | <0.001 |
*Adjusted by age, gender, smoking status, carcinoma in situ, tumor size, tumor grade, and treatment.
BCG: Bacillus Calmette–Guérin immunotherapy; MAF: minor allele frequency; MOI: model of inheritance; rec: recessive; dom: dominant; HR: hazard ratio; CI: confidence interval. Bold font denotes significant P-values.